{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007026","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.781235+00:00","generated_at":"2026-06-18T08:19:03.652105+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neoleukin initiates strategic alternatives review, cuts workforce by 70%, CEO Drachman to step down","bullets":["Engaged SVB Securities to explore sale, merger, asset divestiture, licensing, or other transaction to maximize shareholder value.","Board approved 70% workforce reduction to preserve cash; completion expected in first half of 2023.","CEO Jonathan Drachman, M.D., stepping down after a short transition period.","No assurance that any transaction will occur or on attractive terms; company will not disclose updates until definitive agreements reached."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007026","json":"https://secwatch.observer/filing/0001628280-23-007026.json","markdown":"https://secwatch.observer/filing/0001628280-23-007026.md","text":"https://secwatch.observer/filing/0001628280-23-007026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023007026/0001628280-23-007026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000162828023007026/nltx-20230308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:19:03.652105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}